Synapse Loss in Dementias

Overview

Journal J Neurosci Res

Specialty Neurology

Date 2010 Jun 10

PMID 20533377

Citations 87

Authors

Ryan Clare

Victoria G King

Martin Wirenfeldt

Harry V Vinters

Affiliations

Soon will be listed here.

Abstract

Synaptic transmission is essential for nervous system function, and its dysfunction is a known major contributing factor to Alzheimer's-type dementia. Antigen-specific immunochemical methods are able to characterize synapse loss in dementia through the quantification of various synaptic proteins involved in the synaptic cycle. These immunochemical methods applied to the study of Alzheimer's disease (AD) brain specimens have correlated synaptic loss with particularly toxic forms of amyloid-beta protein and have also established synapse loss as the best correlate of dementia severity. A significant but comparatively circumscribed amount of literature describes synaptic decline in other forms of dementia. Ischemic vascular dementia (IVD) is quite heterogeneous, and synapse loss in IVD seems to be variable among IVD subtypes, probably reflecting its variable neuropathologic correlates. Loss of synaptic protein has been identified in vascular dementia of the Binswanger type and Spatz-Lindenberg's disease. Here we demonstrate a significant loss of synaptophysin density within the temporal lobe of frontotemporal dementia (FTD) patients.

Citing Articles

Investigating the Impact of NMDA Receptor Organization and Biological Sex in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Hadzibegovic S, Bontempi B, Nicole O Int J Mol Sci. 2025; 26(4).

PMID: 40004200 PMC: 11855313. DOI: 10.3390/ijms26041737.

Neurodegeneration in the cortical sulcus is a feature of chronic traumatic encephalopathy and associated with repetitive head impacts.

Nicks R, Shah A, Stathas S, Kirsch D, Horowitz S, Saltiel N Acta Neuropathol. 2024; 148(1):79.

PMID: 39643767 PMC: 11624223. DOI: 10.1007/s00401-024-02833-8.

Controlling Alzheimer's disease by deep brain stimulation based on a data-driven cortical network model.

Yan S, Yang X, Duan Z Cogn Neurodyn. 2024; 18(5):3157-3180.

PMID: 39555293 PMC: 11564625. DOI: 10.1007/s11571-024-10148-3.

Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation.

Bavarsad M, Spina S, Oehler A, Allen I, Suemoto C, Leite R Acta Neuropathol. 2024; 148(1):58.

PMID: 39476256 PMC: 11827533. DOI: 10.1007/s00401-024-02816-9.

FORTCARE-MCI study protocol: evaluation of Fortasyn Connect in the management of mild cognitive impairment in primary care.

Arrieta E, Baz P, Garcia-Ribas G Front Neurol. 2024; 15:1434210.

PMID: 39463791 PMC: 11503483. DOI: 10.3389/fneur.2024.1434210.

References

Ishibashi K, Tomiyama T, Nishitsuji K, Hara M, Mori H . Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain. J Neurosci Res. 2006; 84(3):632-6. DOI: 10.1002/jnr.20952. View

Brown D, Risser R, Bigio E, Tripp P, Stiegler A, Welch E . Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol. 1998; 57(10):955-60. DOI: 10.1097/00005072-199810000-00007. View

Reddy P, Mani G, Park B, Jacques J, Murdoch G, Whetsell Jr W . Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005; 7(2):103-17. DOI: 10.3233/jad-2005-7203. View

Sudhof T . The synaptic vesicle cycle. Annu Rev Neurosci. 2004; 27:509-47. DOI: 10.1146/annurev.neuro.26.041002.131412. View

Samuel W, Alford M, Hofstetter C, Hansen L . Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol. 1997; 56(5):499-508. DOI: 10.1097/00005072-199705000-00006. View

Janz R, Goda Y, Geppert M, Missler M, Sudhof T . SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron. 2000; 24(4):1003-16. DOI: 10.1016/s0896-6273(00)81046-6. View

Ingelsson M, Fukumoto H, Newell K, Growdon J, Hedley-Whyte E, Frosch M . Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004; 62(6):925-31. DOI: 10.1212/01.wnl.0000115115.98960.37. View

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

Kitamoto T, Shin R, Doh-ura K, Tomokane N, Miyazono M, Muramoto T . Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease. Am J Pathol. 1992; 140(6):1285-94. PMC: 1886543. View

10.

Mucke L, Masliah E, Yu G, Mallory M, Rockenstein E, Tatsuno G . High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000; 20(11):4050-8. PMC: 6772621. View

11.

Hansen L, Daniel S, Wilcock G, Love S . Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry. 1998; 64(5):653-6. PMC: 2170082. DOI: 10.1136/jnnp.64.5.653. View

12.

Hamos J, DeGennaro L, Drachman D . Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989; 39(3):355-61. DOI: 10.1212/wnl.39.3.355. View

13.

Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W . Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997; 277(10):813-7. View

14.

Zhan S, Beyreuther K, Schmitt H . Vascular dementia in Spatz-Lindenberg's disease (SLD): cortical synaptophysin immunoreactivity as compared with dementia of Alzheimer type and non-demented controls. Acta Neuropathol. 1993; 86(3):259-64. DOI: 10.1007/BF00304140. View

15.

Geppert M, Goda Y, Hammer R, Li C, Rosahl T, Stevens C . Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse. Cell. 1994; 79(4):717-27. DOI: 10.1016/0092-8674(94)90556-8. View

16.

Honer W . Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals. Neurobiol Aging. 2003; 24(8):1047-62. DOI: 10.1016/j.neurobiolaging.2003.04.005. View

17.

Edelmann L, Hanson P, Chapman E, Jahn R . Synaptobrevin binding to synaptophysin: a potential mechanism for controlling the exocytotic fusion machine. EMBO J. 1995; 14(2):224-31. PMC: 398074. DOI: 10.1002/j.1460-2075.1995.tb06995.x. View

18.

Liu X, Passant U, Risberg J, Warkentin S, Brun A . Synapse density related to cerebral blood flow and symptomatology in frontal lobe degeneration and Alzheimer's disease. Dement Geriatr Cogn Disord. 1999; 10 Suppl 1:64-70. DOI: 10.1159/000051216. View

19.

Soontornniyomkij V, Lynch M, Mermash S, Pomakian J, Badkoobehi H, Clare R . Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol. 2009; 20(2):459-67. PMC: 3127860. DOI: 10.1111/j.1750-3639.2009.00322.x. View

20.

Fernandez-Chacon R, Konigstorfer A, Gerber S, Garcia J, Matos M, Stevens C . Synaptotagmin I functions as a calcium regulator of release probability. Nature. 2001; 410(6824):41-9. DOI: 10.1038/35065004. View